1. US House of Representatives Committee on Oversight and Reform and Committee on Energy and Commerce. The high price of Aduhelm’s approval: an investigation into FDA’s atypical review process and Biogen’s aggressive launch plans. Dec 2022. https://energycommerce.house.gov/sites/democrats.energycommerce.house.gov/files/documents/Final%20Aduhelm%20Report_12.29.22.pdf.
2. Biogen. Corporate statement on report by the staffs of the Committee on Oversight and Reform and Committee on Energy and Commerce. Dec 2022. https://investors.biogen.com/news-releases/news-release-details/corporate-statement-biogen-house-committee-oversight-report.
3. FDA approves controversial Alzheimer’s drug despite uncertainty over effectiveness
4. Three FDA advisory panel members resign over approval of Alzheimer’s drug